1. Weaning & De-escalation Protocols

A. Criteria for Therapy De-escalation

1. Clinical Stabilization Markers

• Hemodynamics: MAP ≥65 mm Hg with no or minimal vasopressor support (norepinephrine <0.05 µg/kg/min for ≥12 h).
• Temperature: Sustained normothermia for ≥24 h.
• Inflammation: WBC trending toward 4,000–11,000/mm³; procalcitonin ↓ ≥80% from peak or <0.5 ng/mL; lactate <2 mmol/L.
• Respiratory: RSBI <105; PaO₂/FiO₂ >200 mm Hg; successful spontaneous breathing trial.
• Neurologic: GCS ≥13; follows simple commands; ready for sedation taper.
• Renal: ↓ serum creatinine; off or weaning renal replacement therapy.

2. Culture-Guided Narrowing

• De-escalate broad-spectrum empiric regimens once susceptibilities are known.
• Example: Vancomycin + piperacillin/tazobactam → cefazolin for MSSA.
• Target %T>MIC for β-lactams; discontinue aminoglycosides when possible.
• In culture-negative sepsis (≥72 h), tailor to most likely source (e.g., cellulitis → first-generation cephalosporin).

B. Discontinuation of Adjunctive Agents

• Clindamycin (toxin suppression): stop after 48–72 h of stability to reduce C. difficile risk.
• Vasopressor adjuncts: discontinue vasopressin when norepinephrine <0.05 µg/kg/min for ≥12 h.
• Steroids: taper hydrocortisone over 3–5 days to prevent adrenal insufficiency rebound.
• Sedation/Analgesia: daily spontaneous awakening trials (SATs) and goal-directed pain scales to minimize delirium.

2. Intravenous to Enteral Conversion

A. Drug Selection for Enteral Route

Prioritize agents with bioavailability ≥80%. Check for drug–drug and drug–food interactions (e.g., fluoroquinolones + antacids).

B. Management of Enteral Access Tubes

• Confirm formulation compatibility: tablets vs. suspensions.
• Flush tubes with 15–30 mL water before and after each medication.
• Stagger medications to avoid occlusion and interaction.

C. Monitoring for Absorption and Efficacy

• Track clinical response, cultures, and biomarkers (e.g., PCT).
• Perform therapeutic drug monitoring when indicated (linezolid troughs, voriconazole).

3. Post-ICU Syndrome (PICS) Prevention

A. Risk Stratification & Early Mobilization

Patients at high risk for PICS include those with an ICU stay ≥7 days, sedation >48 hours, delirium, sepsis, or mechanical ventilation. Initiate passive range of motion and progress to active mobilization as tolerated.

B. ABCDEF Bundle

The ABCDEF bundle is a multicomponent, evidence-based strategy to reduce long-term cognitive, physical, and psychological sequelae of critical illness.

4. Medication Reconciliation & Discharge Planning

A. Comprehensive Reconciliation at Transfer

• Compare admission, ICU, and discharge regimens; discontinue duplications and unnecessary agents.
• Document indication, dose, duration, and monitoring for each medication.

B. Patient & Caregiver Counseling

• Teach the purpose, dosing schedule, and administration techniques (e.g., tube flushing).
• Alert to side effects and warning signs; use the teach-back method to ensure understanding.
• Provide written discharge summaries and medication lists in clear, simple language.

C. Outpatient Parenteral Antimicrobial Therapy (OPAT)

• Eligibility: Hemodynamic/infection stability, reliable IV access, and demonstrated patient/caregiver competence.
• Infrastructure: Coordination with home infusion services, provision of infusion pumps, and scheduled lab monitoring.
• Follow-up: Arrange a clinic or telehealth visit within 3–7 days; monitor CBC, renal function, and drug levels as indicated.

D. Coordination with Primary Care & Specialty Clinics

• Communicate pending culture results and planned regimen adjustments to outpatient providers.
• Arrange rehabilitation or physiatry referrals for continued mobilization and PICS mitigation.